Beigene

This early-stage study tested a new drug called BGB-24714 in 157 adults with advanced solid tumors that had spread or could not be removed by surgery. The main goal was to check the drug's safety and find the best dose when used alone or with chemotherapy or radiation. The study …

This study tested a drug called tislelizumab against standard chemotherapy for people with classical Hodgkin lymphoma that returned or didn't respond to prior treatments. The trial aimed to see if tislelizumab could delay cancer progression. However, the study was stopped early a…

This study tested whether adding ociperlimab to tislelizumab works better than pembrolizumab alone for people with advanced non-small cell lung cancer that hasn't been treated before. Participants had high levels of a protein called PD-L1 on their tumors. The trial was terminated…

This early-stage study tested a new drug called BGB-30813, alone or with another drug (tislelizumab), in people with advanced solid tumors that had not responded to standard treatments. The goal was to check safety and find the right dose. The trial was terminated early, so resul…

This early-phase study tested a new experimental drug, BGB-A3055, alone or with another drug (tislelizumab), in people with advanced solid tumors that had spread. The main goals were to check safety, how the body handles the drug, and whether it shrinks tumors. The study was term…

This early-stage study tested a new drug, BGB-B3227, alone or with another drug (tislelizumab) in 35 people with advanced solid tumors. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.